ENG/中
老虎證券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
武漢艾米森生命科技股份有限公司(臨時代碼)
成交量:
- -
成交額:
- -
市值:
- -
市盈率:
- -
高:
- -
開:
- -
低:
- -
收:
- -
52周最高:
- -
52周最低:
- -
股本:
- -
香港流通股本:
- -
量比:
- -
換手率:
- -
股息:
- -
股息率:
- -
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
市銷率:
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
新股消息 | 艾米森擬港股上市 中國證監會要求補充説明股權變動等事項
智通财经
·
2025/11/14
艾米森衝港股年營收不足千萬元 關聯交易撐起半邊天
中金财经
·
2025/10/30
艾米森衝刺港股 半數收入涉關聯交易
滚动播报
·
2025/10/29
癌症早篩公司艾米森IPO:營收額不足千萬靠縮減費用減虧 關聯方或股東貢獻超6成營收
新浪证券
·
2025/10/24
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易,超低佣金,新手也能轻松开启投资。在老虎证券, 1 美元起投资美股,24/5 无时差交易美股,澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易,超低佣金,新手也能轻松开启投资。在老虎证券, 1 美元起投资美股,24/5 无时差交易美股,澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/91270"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"91270","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91270\",,,,,undefined,":{"symbol":"91270","market":"HK","secType":"STK","nameCN":"武漢艾米森生命科技股份有限公司(臨時代碼)","latestPrice":0,"timestamp":1771214400000,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"農曆年初一休市","change":0,"latestTime":"02-16 12:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771551000000},"marketStatusCode":7,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1771205400000,1771214400000]],"volumeRatio":0,"lotSize":0,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91270\",,,,,undefined,":{"symbol":"91270","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91270\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91270\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91270\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91270\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583950807","title":"新股消息 | 艾米森擬港股上市 中國證監會要求補充説明股權變動等事項","url":"https://stock-news.laohu8.com/highlight/detail?id=2583950807","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583950807?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 19:57","pubTimestamp":1763121472,"startTime":"0","endTime":"0","summary":"中国证监会国际司公示10家企业补充材料要求,其中,公示提到要求艾米森补充说明股权变动、股东情况、业务经营等事项。据港交所9月28日披露,武汉艾米森生命科技股份有限公司向港交所主板提交上市申请书,联席保荐人为建银国际、交银国际。招股书显示,艾米森是一家领先的早期癌症检测公司,战略聚焦于高发病率、高死亡率的癌症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91270"],"gpt_icon":0},{"id":"2579634451","title":"艾米森衝港股年營收不足千萬元 關聯交易撐起半邊天","url":"https://stock-news.laohu8.com/highlight/detail?id=2579634451","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579634451?lang=zh_tw&edition=fundamental","pubTime":"2025-10-30 11:08","pubTimestamp":1761793690,"startTime":"0","endTime":"0","summary":"中国经济网北京10月30日讯 近日,武汉艾米森生命科技股份有限公司 向港交所递交上市申请,联席保荐人为建银国际与交银国际。 新浪证券近日刊载《癌症早筛公司艾米森IPO:营收额不足千万靠缩减费用减亏 关联方或股东贡献超6成营收》。文章指出,2023年、2024年及2025年上半年,艾米森的收入分别为623.3万元、723.8万元和651.3万元。尽管2025年上半年同比增长103%,但整体营收规模仍不足千万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251030/31750212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["91270"],"gpt_icon":0},{"id":"2579491990","title":"艾米森衝刺港股 半數收入涉關聯交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2579491990","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579491990?lang=zh_tw&edition=fundamental","pubTime":"2025-10-29 04:35","pubTimestamp":1761683700,"startTime":"0","endTime":"0","summary":" 近日,武汉艾米森生命科技股份有限公司向港交所递交上市申请,联席保荐人为建银国际与交银国际。 作为一家成立于2015年的公司,艾米森聚焦近年来兴起的癌症早筛技术,自称旗下核心产品艾光乐仅需用1毫升尿液样本即可实现尿路上皮癌的非侵入性检测。但前沿技术的背后,公司至今仍未盈利,还存在研发投入存疑和大额关联交易的情况。 回顾艾米森近年来的业绩表现,大额的关联交易无疑是不容忽视的一环。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-10-29/doc-infvnxkx8370951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91270"],"gpt_icon":0},{"id":"2577552077","title":"癌症早篩公司艾米森IPO:營收額不足千萬靠縮減費用減虧 關聯方或股東貢獻超6成營收","url":"https://stock-news.laohu8.com/highlight/detail?id=2577552077","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577552077?lang=zh_tw&edition=fundamental","pubTime":"2025-10-24 10:38","pubTimestamp":1761273480,"startTime":"0","endTime":"0","summary":" 近日,武汉艾米森生命科技股份有限公司正式向港交所递交招股书,联席保荐人为建银国际与交银国际。艾米森成立于2015年、专注于癌症早期筛查的体外诊断公司,愿景是成为全球肿瘤早筛的领先者。艾米森的上市尝试,恰逢行业标杆企业诺辉健康因财务造假停牌18个月、面临退市危机。被誉为中国癌症早筛第一股的企业坠落神坛,让整个行业笼罩在阴影之中。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-10-24/doc-infuyerp1519536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91270"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/91270\",params:#limit:6,delay:false,,,undefined,":[]}}